Literature DB >> 18787407

Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma.

Tine S Mantoni1, Roy R E Schendel, Franz Rödel, Gerald Niedobitek, Osama Al-Assar, Atsuhi Masamune, Thomas B Brunner.   

Abstract

PURPOSE: Pancreatic stellate cells (PSC) drive desmoplasia in pancreatic cancer. Our study analyzed both tumor and PSC, since interaction of these cell types may promote tumor progression.
RESULTS: SPARC was expressed predominantly in the peritumoral and distal stroma. SPARC in distal stroma correlated inversely with overall survival of the patients with LAPC (p = 0.013) with a relative hazard of 2.23 (95% CI, 1.05 to 4.72; p = 0.036). TGFbeta1 in the tumor was also a negative prognostic factor (p = 0.03). Within the tumor cells, phospho-Akt correlated with TGFbeta1, SPARC and survivin. Tumor phospho-Akt correlated with stroma phospho-Akt, tumor TGFbeta1 correlated with stroma TGFbeta1 and alpha-SMA, tumor survivin correlated with stroma survivin and distal SPARC. Within the stroma, SPARC and TGFbeta1 correlated with alpha-SMA. Peritumoral SPARC correlated with distal SPARC. In vitro, SPARC was highly expressed in hPSC but not in Panc-1 cells. Exogenous SPARC did not change radiation resistance but increased the invasion of Panc-1 cells both in monoculture and in coculture with hPSC. EXPERIMENTAL
DESIGN: Immunohistochemical expression of SPARC, CTGF, TGFbeta1, phospho-Akt, survivin and alpha-SMA was analyzed prior to chemoradiation in 58 locally advanced pancreatic cancer (LAPC) biopsy specimens. Fisher's exact test served to detect associations between tumor and PSC expression of markers. Kaplan-Meier analysis and multivariate analysis were used to evaluate the association of marker expression with overall survival. SPARC expression was analyzed in human pancreatic cancer cells (Panc-1) and in human PSC (hPSC) and the effect of SPARC on the invasion of Panc-1 cells was measured in monoculture or in coculture with hPSC.
CONCLUSIONS: Our hypothesis of a detrimental effect of PSC on patient survival in LAPC after chemoradiation is supported by the inverse correlation of SPARC in distal stromal cells with patients survival. Furthermore in vitro data indicate that paracrine SPARC from PSC increases the invasion of pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18787407     DOI: 10.4161/cbt.7.11.6846

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  50 in total

1.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma.

Authors:  Anne M Delany
Journal:  Cancer Biol Ther       Date:  2010-07-01       Impact factor: 4.742

Review 3.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 4.  Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors.

Authors:  Stephanie E Combs
Journal:  Langenbecks Arch Surg       Date:  2015-07-03       Impact factor: 3.445

Review 5.  Human correlates of provocative questions in pancreatic pathology.

Authors:  Oliver G McDonald; Anirban Maitra; Ralph H Hruban
Journal:  Adv Anat Pathol       Date:  2012-11       Impact factor: 3.875

Review 6.  Pancreatic biomarkers: could they be the answer?

Authors:  Angela Lamarca; Jaime Feliu
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

7.  SPARC is associated with carcinogenesis of oral squamous epithelium and consistent with cell competition.

Authors:  Tomohiro Yamada; Seiji Ohno; Naoya Kitamura; Eri Sasabe; Tetsuya Yamamoto
Journal:  Med Mol Morphol       Date:  2014-10-14       Impact factor: 2.309

Review 8.  Inflammation and pancreatic cancer: disease promoter and new therapeutic target.

Authors:  Shin Hamada; Atsushi Masamune; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2013-11-30       Impact factor: 7.527

Review 9.  Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.

Authors:  Michael Friberg Bruun Nielsen; Michael Bau Mortensen; Sönke Detlefsen
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 10.  Regulation of pancreatic function by connective tissue growth factor (CTGF, CCN2).

Authors:  Alyssa Charrier; David R Brigstock
Journal:  Cytokine Growth Factor Rev       Date:  2012-08-10       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.